Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 5Phase 1/2 4Phase 3 3Phase 2/3 2

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Gastrointestinal 1

Conditions

HER2-positive Breast Cancer 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × tucatinib × Clear all
NCT05253651 2026-06-04

MOUNTAINEER-03

Seagen Inc.

Phase 3 Recruiting
400 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05132582 2026-04-20

HER2CLIMB-05

Seagen Inc.

Phase 3 Active not recruiting
654 enrolled
Breast

Breast Neoplasms

NCT03975647 2026-03-30

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Seagen Inc.

Phase 3 Active not recruiting
466 enrolled 17 charts
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡